All In Biotech

Drug Trial Radar · NCT06858319

Open-label Extension Study of Zigakibart in Adults With IgA Nephropathy.

A Multicenter Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Zigakibart in Adults With Primary IgA Nephropathy.

Last checked: Nov 19, 2026Latest source record: Aug 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

220

Planned (sponsor's estimate)

Start

Jul 28, 2025

Primary completion

Jun 25, 2031

Study completion Jun 25, 2031

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Mar 5, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 100 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine if zigakibart is safe and effective for long-term use in patients with immunoglobulin A nephropathy (IgAN). This is an extension study for patients who have already completed an another zigakibart study.

Conditions

  • Kidney Diseases
  • Kidney Diseases, Chronic
  • Urological Diseases
  • Glomerulonephritis
  • Glomerular Disease
  • Glomerulonephritis, IGA
  • Glomerulopathy
  • Immunoglobulin Disease

Interventions

  • zigakibartDrug

    solution for subcutaneous injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with adverse events.Time frame: Date of first administration of study treatment to 24 weeks after the date of the last actual administration of study treatment
  2. Number of participants with serious adverse events.Time frame: Date of first administration of study treatment to 24 weeks after the date of the last actual administration of study treatment
  3. Number of participants with adverse events of special interest.Time frame: Date of first administration of study treatment to 24 weeks after the date of the last actual administration of study treatment

Locations

26 sites in 9 countries. Site status is shown where the registry gives one.

  • Colorado Kidney Care Nephrology

    Denver, Colorado · Recruiting

  • Nephrology Associates Of Central FL

    Orlando, Florida · Recruiting

  • University of Iowa Hospitals and Clinics

    Iowa City, Iowa · Recruiting

  • NY Nephrology

    Clifton Park, New York · Recruiting

  • Icahn School of Medicine at Mount Sinai

    New York, New York · Recruiting

  • Knoxville Kidney Center Pllc

    Brentwood, Tennessee · Recruiting

  • Dallas Renal Group

    Dallas, Texas · Recruiting

  • Dallas Renal Group

    Dallas, Texas · Recruiting

  • Nephro Asso North Illinois Indiana

    Houston, Texas · Recruiting

  • Novartis Investigative Site

    Santa Fe, Argentina · Recruiting

  • Novartis Investigative Site

    Caba, Buenos Aires, Argentina · Recruiting

  • Novartis Investigative Site

    La Plata, Buenos Aires, Argentina · Recruiting

  • Novartis Investigative Site

    Buenos Aires, Buenos Aires F.D., Argentina · Recruiting

  • Novartis Investigative Site

    Catamarca, Catamarca Province, Argentina · Recruiting

  • Novartis Investigative Site

    Gosford, New South Wales, Australia · Recruiting

  • Novartis Investigative Site

    Kogarah, New South Wales, Australia · Recruiting

  • Novartis Investigative Site

    Toronto, Ontario, Canada · Recruiting

  • Novartis Investigative Site

    Kuala Lumpur, Malaysia · Recruiting

  • Novartis Investigative Site

    Kuantan, Pahang, Malaysia · Recruiting

  • Novartis Investigative Site

    Monterrey, Nuevo León, Mexico · Recruiting

  • Novartis Investigative Site

    Cheonan, Chungcheongnam-do, South Korea · Recruiting

  • Novartis Investigative Site

    Guri-si, Gyeonggi-do, South Korea · Recruiting

  • Novartis Investigative Site

    Seongnam-si, Gyeonggi-do, South Korea · Recruiting

  • Novartis Investigative Site

    Seoul, Seoul, South Korea · Recruiting

  • Novartis Investigative Site

    Girona, Catalonia, Spain · Recruiting

  • Novartis Investigative Site

    Taipei, Taiwan · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.